Exhaled breath drug detection using differential mobility spectrometry

项目摘要 这项建议旨在扩大呼吸分析技术，正在积极研究的重点是美国国立卫生研究院 授权#6R42DA049655-02，并利用该技术进行快速COVID-19诊断。我们迫切需要 用于快速进行的COVID-19敏感和特异性诊断测试。微分迀移 目前正在研究的用于药物检测的光谱测定法（DMS）呼吸分析技术可以适用于 来填补这个空白 在此补充期间，我们将进行生物标志物发现工作，以确定呼出气体分子 最适合用作COVID-19生物标志物的物种。一旦确定了目标物种， 将研究在COVID-19检测的安全范式内可以实施的捕获。 我们还将启动与FDA的对话，并制定FDA批准策略，以加快部署 未来基于呼吸的COVID-19诊断仪器的基础上正在研究的技术， 行政补贴的父母补助金。

Project Summary This proposal seeks to expand upon breath analysis technology that is being actively studied as the focus of NIH grant #6R42DA049655-02 and leverage this technology for rapid COVID-19 diagnostics. There is a dire need for sensitive and specific diagnostic tests for COVID-19 that can be performed quickly. The differential mobility spectrometry (DMS) breath analysis technology currently under investigation for drug detection may be adapted to fill this void. During this supplement we will perform a biomarker discovery effort to determine the exhaled breath molecular species most suitable for use as a COVID-19 biomarker. Once a target species has been identified, methods of capture that can be implemented within the safety paradigm governing COVID-19 testing will be investigated. We will also initiate conversation with the FDA and develop an FDA approval strategy to expedite the deployment of a future breath based COVID-19 diagnostic instrument based upon the technology being studied under this administrative supplement’s parent grant.